147 related articles for article (PubMed ID: 19912736)
21. The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Evans WK; Kocha W; Gagliardi A; Eady A; Newman TE
Cancer Prev Control; 1999 Feb; 3(1):84-94. PubMed ID: 10474757
[TBL] [Abstract][Full Text] [Related]
22. [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Shen L; Xu JM; Feng FY; Jiao SC; Wang LW; Li J; Guan ZZ; Qin SK; Wang JJ; Yu SY; Wang YJ; Jin YN; Tao M; Zheng LZ; Pan LX
Zhonghua Zhong Liu Za Zhi; 2013 Apr; 35(4):295-300. PubMed ID: 23985260
[TBL] [Abstract][Full Text] [Related]
23. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Zatloukal P; Petruzelka L; Zemanová M; Kolek V; Skricková J; Pesek M; Fojtů H; Grygárková I; Sixtová D; Roubec J; Horenková E; Havel L; Průsa P; Nováková L; Skácel T; Kůta M
Lung Cancer; 2003 Sep; 41(3):321-31. PubMed ID: 12928123
[TBL] [Abstract][Full Text] [Related]
24. Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Hu L; Liang G; Yuliang W; Bingjing Z; Xiangdong Z; Rufu X
Trials; 2013 Feb; 14():45. PubMed ID: 23413951
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions.
Wang J; Zhao Q; Cai L; Li J; Chen S
Biomed Res Int; 2022; 2022():2317181. PubMed ID: 35480138
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
[TBL] [Abstract][Full Text] [Related]
27. Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.
Urba SG; Chansky K; VanVeldhuizen PJ; Pluenneke RE; Benedetti JK; Macdonald JS; Abbruzzese JL;
Invest New Drugs; 2004 Jan; 22(1):91-7. PubMed ID: 14707499
[TBL] [Abstract][Full Text] [Related]
28. Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Shelley M; Cleves A; Wilt TJ; Mason M
Cochrane Database Syst Rev; 2011 Apr; (4):CD008976. PubMed ID: 21491413
[TBL] [Abstract][Full Text] [Related]
29. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Kitamura H; Takahashi A; Hotta H; Kato R; Kunishima Y; Takei F; Horita H; Masumori N;
Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
[TBL] [Abstract][Full Text] [Related]
30. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
[TBL] [Abstract][Full Text] [Related]
31. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Cascinu S; Berardi R; Labianca R; Siena S; Falcone A; Aitini E; Barni S; Di Costanzo F; Dapretto E; Tonini G; Pierantoni C; Artale S; Rota S; Floriani I; Scartozzi M; Zaniboni A;
Lancet Oncol; 2008 Jan; 9(1):39-44. PubMed ID: 18077217
[TBL] [Abstract][Full Text] [Related]
32. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
Sandler AB; Nemunaitis J; Denham C; von Pawel J; Cormier Y; Gatzemeier U; Mattson K; Manegold C; Palmer MC; Gregor A; Nguyen B; Niyikiza C; Einhorn LH
J Clin Oncol; 2000 Jan; 18(1):122-30. PubMed ID: 10623702
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Shi X; Yu XM; Zhang YP; Zhao J
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of cisplatin combined with gemcitabine versus cisplatin combined with vinorelbine regimen for treatment of patients with advanced non-small cell lung cancer].
Teng XY; Zhou NN; Su YS; Zhou ZM; Liu DG; He YJ
Ai Zheng; 2003 Apr; 22(4):404-6. PubMed ID: 12703999
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer.
van Zweeden AA; van Groeningen CJ; Honeywell RJ; Giovannetti E; Ruijter R; Smorenburg CH; Giaccone G; Verheul HMW; Peters GJ; van der Vliet HJ
Cancer Chemother Pharmacol; 2018 Jul; 82(1):39-48. PubMed ID: 29696360
[TBL] [Abstract][Full Text] [Related]
36. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
[TBL] [Abstract][Full Text] [Related]
37. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Cardenal F; López-Cabrerizo MP; Antón A; Alberola V; Massuti B; Carrato A; Barneto I; Lomas M; García M; Lianes P; Montalar J; Vadell C; González-Larriba JL; Nguyen B; Artal A; Rosell R
J Clin Oncol; 1999 Jan; 17(1):12-8. PubMed ID: 10458212
[TBL] [Abstract][Full Text] [Related]
38. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Shroff RT; Javle MM; Xiao L; Kaseb AO; Varadhachary GR; Wolff RA; Raghav KPS; Iwasaki M; Masci P; Ramanathan RK; Ahn DH; Bekaii-Saab TS; Borad MJ
JAMA Oncol; 2019 Jun; 5(6):824-830. PubMed ID: 30998813
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
[TBL] [Abstract][Full Text] [Related]
40. A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Kameda R; Ando T; Kobayashi S; Ueno M; Ohkawa S
Jpn J Clin Oncol; 2013 Jun; 43(6):636-40. PubMed ID: 23619988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
